Tenecteplase preferred for acute ischemic stroke thrombolysis

Dr. Wasif Rizwan Malik | MBBS, FCPS (Neurosurgery) | PMDC 47983-P Consultant Neurosurgeon, Faraz Hospital, Bahawalpur

When every minute of brain ischemia costs neurons, the practical details of how a clot-busting drug is given matter as much as the drug itself. Growing clinical evidence and guideline updates increasingly favour tenecteplase over alteplase for eligible adults with acute ischemic stroke, largely because a single intravenous bolus can replace a prolonged infusion—an advantage that is especially relevant for busy Pakistani stroke pathways with limited pumps, nursing time, and inter-facility transfer capacity.

What changed / Why it matters

For years, intravenous thrombolysis with alteplase (tissue plasminogen activator) was the standard medical reperfusion option within the approved time window for carefully selected patients without contraindications. Alteplase requires a bolus plus a one-hour infusion, which ties up an infusion pump, demands uninterrupted monitoring during administration, and complicates care when patients must move quickly to CT angiography, endovascular teams, or another hospital.

Tenecteplase, a genetically modified variant of tPA with greater fibrin specificity and a longer half-life, is given as a single weight-based bolus over seconds. Large comparative trials and meta-analyses have shown that, at stroke-appropriate doses, tenecteplase is at least as effective as alteplase for early recanalization and functional outcomes in many eligible patients, with a similar overall safety profile regarding symptomatic intracranial haemorrhage when used under protocol. Several international guideline bodies now list tenecteplase as a reasonable—or preferred—alternative to alteplase for intravenous thrombolysis in acute ischemic stroke.

For Pakistani teams facing a high stroke burden, delayed presentations, and uneven access to continuous infusion resources, bolus dosing can reduce door-to-needle friction, free staff during the critical hyperacute phase, and simplify transfer after thrombolysis. It does not replace imaging, checklist-based eligibility review, blood-pressure control, or the need for centres capable of managing haemorrhage and offering endovascular therapy when large-vessel occlusion is present. Neurosurgery and stroke services still rely on rapid recognition, non-contrast CT (and vascular imaging as indicated), glucose and coagulation assessment, and clear post-thrombolysis monitoring—whether the agent is tenecteplase or alteplase.

Patient takeaway

Stroke is a time-critical emergency. Sudden face droop, arm weakness, speech difficulty, or vision/balance change means call emergency services immediately—do not wait for symptoms to “settle.” Only a hospital team can decide if thrombolysis is safe; not every patient qualifies, and imaging must exclude bleed. Ask your local hospital whether stroke thrombolysis pathways and neurosurgical backup are available. *فالج کے شبہے پر فوراً ہسپتال پہنچیں؛ وقت بچانا دماغ بچانا ہے۔*

Disclaimer

This post is for general education only and is not medical advice or a diagnosis for any individual. Stroke treatment decisions require in-person emergency assessment, appropriate imaging, and local protocols. Drug choice, dose, and eligibility must be determined by the treating clinicians.

Book consultation: [https://rx.drwasifmalik.com](https://rx.drwasifmalik.com) | WhatsApp: +923458254232

Educational only — not a substitute for clinical consultation. This daily brief is separate from the weekly Neuro Council deep-dive.

Book a consultation